Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of ICU stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐specific mortality ‐ SJS and TEN (time to · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
It is very uncertain whether intravenous immunoglobulin (IVIG) changes SJS/TEN‐specific mortality (time to compared with no IVIG (very low certainty).
1 finding from 1 review
Time to complete re‐epithelialisation ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
1 finding from 1 review
Duration of ICU stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
1 finding from 1 review
Incidence of acute bilirubin encephalopathy · newborn infants with unconjugated hyperbilirubinaemia undergoing phototherapy
1 finding from 1 review
Bilirubin (µmol/L) · newborn infants with unconjugated hyperbilirubinaemia undergoing phototherapy
1 finding from 1 review
Proportion of infants who required exchange transfusion · newborn infants with unconjugated hyperbilirubinaemia undergoing phototherapy
Intravenous fluid supplementation may leads to lower proportion of infants who required exchange transfusion compared with no fluid supplementation (low certainty).
1 finding from 1 review
Frequency of breastfeeding per day · newborn infants with unconjugated hyperbilirubinaemia undergoing phototherapy
1 finding from 1 review
Number of infants with abnormal neurological signs · newborn infants with unconjugated hyperbilirubinaemia undergoing phototherapy
1 finding from 1 review
Bilirubin (µmol/L) · newborn infants with unconjugated hyperbilirubinaemia undergoing phototherapy
1 finding from 1 review
Rate of change in bilirubin (μmol/L/hour): during the first 4 hours of admission · newborn infants with unconjugated hyperbilirubinaemia undergoing phototherapy
1 finding from 1 review
Eradication of P aeruginosa from the respiratory tract: number of participants testing negative for P aeruginosa at 3 months and remaining free until 15 months · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 % predicted · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
FVC · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Mean weight‐for‐age z‐score · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Frequency of infective pulmonary exacerbations: number of participants experiencing an exacerbation · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
Intravenous ceftazidime with tobramycin showed no clear difference in frequency of infective pulmonary exacerbations: number of… compared with oral ciprofloxacin (high certainty).
1 finding from 1 review